Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs
Flagship旗下的Generate:Biomedicines递交IPO申请，主打AI驱动药物

Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO.
在为首位受试者给药仅九天后，Generate:Biomedicines 已提交IPO申请。